Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study

AIM: There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders. METHODS: This one‐week, prospective, single‐arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18–64 or 15 mg if age ≥ 65 years) for insomnia included 57 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kishi, Taro, Sakuma, Kenji, Okuya, Makoto, Ninomiya, Kohei, Oya, Kazuto, Kubo, Momoko, Matsui, Yuki, Nomura, Ikuo, Okuyama, Yuji, Matsunaga, Shinji, Iwata, Nakao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Micro Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292311/
https://www.ncbi.nlm.nih.gov/pubmed/31283862
http://dx.doi.org/10.1002/npr2.12069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292311/
https://www.ncbi.nlm.nih.gov/pubmed/31283862
http://dx.doi.org/10.1002/npr2.12069

Ejemplares similares